ArticleNeurochemical research2009
Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease.
Article in Neurochemical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- A systematic review and meta-analysis of metalloproteinases in patients with Alzheimer's disease and mild cognitive impairment.Journal of Alzheimer's disease : JAD · 2026Pooled it
- The roles of biomarkers of oxidative stress and antioxidant in Alzheimer's disease: a systematic review.BioMed research international · 2014Pooled it
- Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study.The journal of nutrition, health & aging · 2025Trial
- Impaired Oxidative Stress Markers and Activities of Matrix Metalloproteinases in Plasma of Patients with Alzheimer's Disease, Emphasizing Sex andInternational journal of molecular sciences · 2025Article
- The Link Between Matrix Metalloproteinases and Alzheimer's Disease Pathophysiology.Molecular neurobiology · 2025Review
- Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.Cellular and molecular neurobiology · 2022Review
- Glutathione Peroxidase Activity Is Altered in Vascular Cognitive Impairment-No Dementia and Is a Potential Marker for Verbal Memory Performance.Journal of Alzheimer's disease : JAD · 2021Article
- The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery : NGF Pathway Biomarkers and Drug Targets.Advances in experimental medicine and biology · 2021Article
- Simvastatin Attenuates Hippocampal MMP-9 Expression in the Streptozotocin-Induced Cognitive ImpairmentIranian biomedical journal · 2019Article
- Brain cell apoptosis inhibition by butylphthalide in Alzheimer's disease model in rats.Experimental and therapeutic medicine · 2017Article
- Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update.Archives of toxicology · 2015Review
- Association of the C47T Polymorphism in SOD2 with Amnestic Mild Cognitive Impairment and Alzheimer's Disease in Carriers of the APOEε4 Allele.Disease markers · 2015Article
- Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKD.European child & adolescent psychiatry · 2015Article
- Imaging proteomics for diagnosis, monitoring and prediction of Alzheimer's disease.NeuroImage · 2014Article
- Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment.BioMed research international · 2014Article
- Blood markers of oxidative stress in Alzheimer's disease.Journal of cellular and molecular medicine · 2012Review
- Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment.Journal of Alzheimer's disease : JAD · 2012Article
- Cerebrospinal fluid and blood biomarkers in Alzheimer's disease.World journal of psychiatry · 2011Review
- Oxidative stress and β-amyloid protein in Alzheimer's disease.Neuromolecular medicine · 2011Review
- Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels.Neuroscience letters · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs) and oxidative stress have been implicated in neurological diseases such as Alzheimer's disease (AD). Plasma MMP-2 and MMP-9 activities were assessed in Mild Cognitive Impairment (MCI) and AD subjects compared with aged-matched controls, and subsequently analysed in relation to oxidative stress markers. Both MMP-2 and MMP-9 showed no significant changes versus control subjects. Plasma glutathione peroxidase Se-dependent (GPx-Se) activity and malondialdehyde (MDA) levels were higher in AD than in controls (P < 0.05), suggesting a role for GPx-Se in controlling oxidative stress in AD. Negative correlations were observed between MMPs and MDA in AD and MCI patients (P < 0.05). In conclusion, oxidative stress events did not include activation of MMPs and this similar pattern in AD and MCI suggests that both are biochemically equivalent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.